XORTX Therapeutics Inc Dossier
Qualitative Analysis
Business overview
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease. The company's proprietary technology targets aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. Its lead clinical program is XRx-026, which utilizes a proprietary oral oxypurinol formulation (XORLO™) for the treatment of gout in patients who are intolerant to allopurinol. Additionally, XORTX is developing XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), XRx-101 for acute kidney injury associated with respiratory virus infections, XRx-225 for Type 2 diabetic nephropathy, and the recently acquired pre-IND stage VB4-P5 program targeting rare and prevalent kidney diseases.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing and accelerating the development of XRx-026, leveraging formulation development and clinical validation of the proprietary XORLO™ formulation.
Expected impact: Addresses a substantial unmet medical need in a USD $700 million annual market.
Voluntarily delisting from the TSX Venture Exchange (TSXV) to streamline operations and eliminate duplicative administrative costs, while maintaining its primary listing on the Nasdaq Capital Market.
Expected impact: Reduces administrative complexity and preserves cash for clinical development.
Advancing XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD) toward a Phase 3 registration trial, with plans to seek FDA review under the Accelerated Approval program.
Expected impact: Provides a potential disease-modifying therapy for a rare renal disorder with accelerated approval endpoints.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of the pre-IND stage VB4-P5 small-molecule program, including associated intellectual property, regulatory documentation, and manufacturing data, to target kidney fibrosis in both rare and common chronic kidney diseases [1.1.1].
Financial impact: The transaction was structured entirely using equity (154,544 common shares and 692,150 pre-funded warrants), preserving immediate cash reserves for clinical trials.